Here are relevant reports on : nuclear-medicine-market
-
AI in Precision Medicine Market by Application (Drug Discovery, Screening, Diagnosis, Stratification, Staging, Prognosis, Therapy Selection, Monitoring, Risk Management), Indication (Cancer, CNS, CVS), Tools (ML, NLP), & End User -Global Forecast to 2030
The global AI in Precision Medicine market, valued at US$0.60 billion in 2023, stood at US$0.78 billion in 2024 and is projected to advance at a resilient CAGR of 30.7% from 2024 to 2030, culminating in a forecasted valuation of US$3.92 billion by the end of the period. Growth in precision medicine, AI’s efficiency in drug discovery, integration of Real-World Evidence (RWE) in emerging markets to drive the market significantly.
- Published: November 2024
- Price: $ 4950
- TOC Available:
-
Fluorometer Market by Light source (Lamps, LEDs, Diode Lasers, and Lasers), Application (Chemistry/Biochemistry, Medicine & Others), and End User (Hospitals, Pharmaceutical and Biotechnology Firms & CROs, Others) - Global Forecast to 2023
The global Fluorometer market is expected to reach USD 668.2 million by 2023 from USD 521.1 million in 2018, growing at a CAGR of 5.1%. Increasing incidence of cancer, advancement in cancer diagnostics, technological advancement in fluorometry are some of the major factors driving the growth of the global fluorometer market. These driving factors consequence to the rapid adoption of these new devices, thus propelling the market growth.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Precision Medicine Software Market by Delivery Mode (On-Premise & Cloud-Based), End User (Healthcare Providers, Research Centers & Government Institutes, Pharmaceutical & Biotechnology Companies), Application, and Region - Global Forecast to 2024
The precision medicine software market is projected to reach USD 2.0 billion by 2024, at a CAGR of 11.5%. Factors such as the rising government funding in precision medicine initiatives, partnerships among pharmaceutical and software companies, the entry of new players & VC funding, and growth in the number of cancer patients are driving the growth of the precision medicine software market. However, the high cost of deployment, issues related to the secure storage of large volumes of sequenced data, lack of reimbursement for precision medicine-based treatments, and the dearth of skilled IT professionals in healthcare are expected to restrain market growth to a certain extent in the coming years. Syapse, Inc. (US), 2bPrecise LLC (Israel), Foundation Medicine, Inc. (US), Fabric Genomics (US), SOPHiA GENETICS SA (Switzerland), PierianDx, Inc. (US), N-of-One, Inc. (US), Human Longevity, Inc. (US), Translational Software, Inc. (US), Sunquest Information Systems Inc. (US), Gene42, Inc. (Canada), LifeOmic Health, LLC (US), NantHealth, Inc. (US), Tempus Labs, Inc. (US), Flatiron Health, Inc. (US), IBM Watson Group (US), and Koninklijke Philips N.V. (Netherlands)
- Published: March 2019
- Price: $ 4950
- TOC Available:
-
Europe Artificial Intelligence (AI) in Healthcare Market by Offering (Integrated), Function (Diagnosis, Genomic, Precision Medicine, Radiation, Telehealth, RPM, Immunotherapy, Supply Chain), Application (Clinical), End User (Hospitals) - Forecast to 2030
The Europe Artificial Intelligence (AI) in Healthcare Market, valued at USD 4.20 billion in 2024, stood at USD 6.12 billion in 2025 and is projected to advance at a resilient CAGR of 39.0% from 2025 to 2030, culminating in a forecasted valuation of USD 31.72 billion by the end of the period. This growth is driven by strong regulatory support for digital transformation and the rising adoption of AI-enabled clinical workflows across European health systems.
- Published: December 2025
- Price: $ 4950
- TOC Available:
-
US Artificial Intelligence (AI) in Healthcare Market by Offering (Integrated), Function (Diagnosis, Genomic, Precision Medicine, Radiation, Telehealth, Immunotherapy, Pharmacy, Supply Chain), Application (Clinical), End User (Hospitals) - Forecast to 2030
The US artificial intelligence (AI) in healthcare market, valued at US$5.98 billion in 2024, stood at US$8.65 billion in 2025 and is projected to advance at a resilient CAGR of 38.0% from 2025 to 2030, culminating in a forecasted valuation of US$43.30 billion by the end of the period. Market growth is driven by rising demand from providers for automation, nationwide labor shortages, increasing clinical complexity, and strong investment in predictive analytics, imaging AI, and GenAI.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Poultry Medicine/Pharmaceuticals Market by Animal Type (Chickens, Turkeys, Ducks), Product (Drugs, Vaccines, Feed Additives), Disease Indication (Newcastle disease, Infectious Bursal Disease, Salmonella), Route of Administration - Global Forecast to 2029
The global poultry medicine/pharmaceuticals market, valued at US$4.73 billion in 2023, stood at US$5.01 billion in 2024 and is projected to advance at a resilient CAGR of 5.9% from 2024 to 2029, culminating in a forecasted valuation of US$6.68 billion by the end of the period. The growth of the poultry medicine/pharmaceutical industry can be attributed to the rising global population and consumption of poultry meat and eggs leading to more poultry farming practiced notably in the developing regions where poultry is the cheapest source of protein.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Nucleic Acid Isolation and Purification Market by Product (Kits, Reagents, Instruments), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA), Application (Diagnostics, Personalized Medicine), End User (CROs), Region - Global Forecast to 2030
The global nucleic acid isolation and purification market, valued at US$6.67 billion in 2024, stood at US$7.10 billion in 2025 and is projected to advance at a resilient CAGR of 9.1% from 2025 to 2030, culminating in a forecasted valuation of US$10.99 billion by the end of the period. The global market for nucleic acid isolation and purification (NAIP) is expanding largely due to the increased use of PCR and NGS in clinical diagnostics and research. Laboratories globally require DNA/RNA of high purity and free of inhibitors in order to carry out reliable workflows for sequencing, oncology panels and routine molecular testing.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
3D Bioprinting Market by Component (3D bioprinters (Microextrusion, Inkjet, Laser), Bioinks, Software, Consumable), Material (Hydrogels, ECM), Application (Research (Regenerative Medicine, 3D cell Culture), Clinical (Skin, Bone)) - Global Forecast to 2029
The global 3D bioprinting market, valued at US$1.2 billion in 2023, stood at US$1.3 billion in 2024 and is projected to advance at a resilient CAGR of 12.7% from 2024 to 2029, culminating in a forecasted valuation of US$2.4 billion by the end of the period. The market growth is fueled by the growing adoption of 3D bioprinting technology in the pharmaceutical and cosmetic industries, technological advancements in 3D bioprinting, and the rising demand for organ transplants.
- Published: May 2024
- Price: $ 4950
- TOC Available:
-
Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029
The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, stood at US$145.53 billion in 2024 and is projected to advance at a resilient CAGR of 11.1% from 2024 to 2029, culminating in a forecasted valuation of US$246.66 billion by the end of the period. Factors such as the growing integration of AI and ML to enhance precision diagnostics and medicine development supported by rising collaborations between pharmaceutical and diagnostics companies to improve precision healthcare and the rise in direct-to-consumer testing are driving the growth in the market.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Cell Line Development Market by Product (Equipment, Media and Reagents), Source, type & by Application ( Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) - Analysis & Global Forecast to 2019
The global cell line development market is expected to reach 3.96 billion by 2019 from $2.2 billion in 2014, and is expected to grow at a CAGR of 12.5% from 2014 to 2019. The market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). North America is expected to maintain its leadership position in the market in the coming years.
- Published: September 2014
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
